Abstract
The last few years have seen the transfer of two decades of research into Chimeric Antigen Receptors (CARs) into clinical trials. Despite this extensive research, there is still a great deal of debate into the optimal design strategy for these, primarily, anti-cancer entities. The archetypal CAR consists of a single-chain antibody fragment, specific to a tumour- associated antigen, fused to a component of the T-cell receptor complex (typically CD3ζ) which on antigen binding primes the engrafted T-cell for anti-tumour activity. The modular nature of these artificial receptors has enabled researchers to modify aspects of their structure, including the extracellular spacer, transmembrane and cytoplasmic domain, to achieve laboratory defined optimal activity. Despite this there is no consensus on the optimal structure, a problem exacerbated by conflicting results using identical receptors. In this review, we provide a structural overview of CAR development and highlight areas that require further refinement. We also attempt to identify possible reasons for conflicting results in the hope that this information will inspire future rational design strategies for optimal tumour targeting using CARs.
Keywords: CD3ζ, T-cell Receptor, immunotherapy, gene-transfer, T-cell, costimulation, cancer, scFv
Current Gene Therapy
Title: Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy
Volume: 10 Issue: 2
Author(s): John S. Bridgeman, Robert E. Hawkins, Andreas A. Hombach, Hinrich Abken and David E. Gilham
Affiliation:
Keywords: CD3ζ, T-cell Receptor, immunotherapy, gene-transfer, T-cell, costimulation, cancer, scFv
Abstract: The last few years have seen the transfer of two decades of research into Chimeric Antigen Receptors (CARs) into clinical trials. Despite this extensive research, there is still a great deal of debate into the optimal design strategy for these, primarily, anti-cancer entities. The archetypal CAR consists of a single-chain antibody fragment, specific to a tumour- associated antigen, fused to a component of the T-cell receptor complex (typically CD3ζ) which on antigen binding primes the engrafted T-cell for anti-tumour activity. The modular nature of these artificial receptors has enabled researchers to modify aspects of their structure, including the extracellular spacer, transmembrane and cytoplasmic domain, to achieve laboratory defined optimal activity. Despite this there is no consensus on the optimal structure, a problem exacerbated by conflicting results using identical receptors. In this review, we provide a structural overview of CAR development and highlight areas that require further refinement. We also attempt to identify possible reasons for conflicting results in the hope that this information will inspire future rational design strategies for optimal tumour targeting using CARs.
Export Options
About this article
Cite this article as:
S. Bridgeman John, E. Hawkins Robert, A. Hombach Andreas, Abken Hinrich and E. Gilham David, Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy, Current Gene Therapy 2010; 10 (2) . https://dx.doi.org/10.2174/156652310791111001
DOI https://dx.doi.org/10.2174/156652310791111001 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in Boron Neutron Capture Therapy (BNCT) Driven by Nanotechnology
Current Chemical Biology Clonetics
Current Drug Metabolism Non-Invasive Imaging of Complicated Osteomyelitis: The Added Value of Scintigraphic Techniques
Current Radiopharmaceuticals Potential of Selected Antioxidants for Influenza Chemotherapy
Anti-Infective Agents in Medicinal Chemistry Ovulation Inducing Agents and Cancer Risk: Review of Literature
Current Drug Safety Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects
Current Drug Metabolism Use of Naturally Occurring Peptides for Neuropathic Spinal Cord Injury Pain
Current Protein & Peptide Science O6-Alkylguanine-DNA Alkyltransferase Inactivation in Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry Reversal of Bone Cancer Pain by HSV-1-Mediated Silencing of CNTF in an Afferent Area of the Spinal Cord Associated with AKT-ERK Signal Inhibition
Current Gene Therapy Caspases as Drug Targets in Ischemic Organ Injury
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design Antiproliferative and Pro-Apoptotic Effects of Thiazolo[3,2–b][1,2,4]triazoles in Breast and Cervical Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Apoptosis: Potential Therapeutic Targets for New Drug Discovery
Current Medicinal Chemistry Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling
Current Genomics Sentinel Node Imaging
Current Medical Imaging Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience An Insight of Molecular Mechanisms and Patents of Biomarkers of Human Papilloma Virus Associated with Cancer : A Review
Recent Patents on Biomarkers Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Current Topics in Medicinal Chemistry Recent Progress on Apoptotic Activity of Triazoles
Current Drug Targets A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens
Protein & Peptide Letters